AstraZeneca schedules digital AGM for April 11, 2025

LONDON - AstraZeneca PLC (LON:AZN) announced that its 2025 Annual General Meeting (AGM) will be hosted digitally on April 11 at 14:30 (BST). The Notice of AGM and Shareholders’ Circular has been published and is now accessible for shareholder review.

The AGM agenda includes the review of the company’s 2024 financial accounts, director reports, and strategic insights. Shareholders will also consider the confirmation of 2024 interim dividends and the re-appointment of PricewaterhouseCoopers LLP as the company’s auditor, along with the authorization for directors to set the auditor’s remuneration.

Additional items on the agenda are the election or re-election of company directors, approval of the remuneration report, and authorization for limited political donations. Shareholders will also vote on resolutions allowing the directors to allot shares, disapply pre-emption rights, and further disapply these rights for specific acquisitions and capital investments. Moreover, the meeting will address the authorization for the company to purchase its own shares and potentially reduce the notice period for general meetings.

Shareholders must be registered by 18:30 (BST) on April 9, 2025, to attend and vote at the AGM or by the same time two days prior to any adjourned meeting. The record dates for determining voting eligibility differ for holders of ordinary shares, American Depositary Receipts, and those in the Euroclear Sweden system.

AstraZeneca (NASDAQ:AZN), a biopharmaceutical company with a focus on Oncology, Rare Diseases, and various BioPharmaceuticals, has a global presence, with its innovative medicines reaching over 125 countries.

The information regarding the AGM is based on a press release statement and has been made available through the National Storage Mechanism and on AstraZeneca’s official website.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.